Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6875978 | 0.87 | KMT2A (0.51) | TDP1KMT2ASLC6A2SLC6A3PPARG | |
| SCHEMBL6472102 | 0.86 | TDP1 (0.57) | TDP1KMT2ASLC6A2SLC6A3PPARG | |
| SCHEMBL6245188 | 0.82 | PPARG (0.61) | TDP1KMT2ASLC6A2SLC6A3PPARG | |
| SCHEMBL4650584 | 0.82 | KMT2A (0.76) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL28984037 | 0.81 | TDP1 (0.69) | TDP1KMT2ASLC6A2SLC6A3PPARG | |
| SCHEMBL5085480 | 0.80 | PPARG (0.71) | TDP1KMT2ASLC6A2SLC6A3PPARG | |
| SCHEMBL6564486 | 0.78 | TDP1 (0.54) | TDP1KMT2ASLC6A2SLC6A3PPARG | |
| SCHEMBL16758178 | 0.78 | TDP1 (0.69) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL6511919 | 0.78 | KMT2A (0.73) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL5085718 | 0.76 | KMT2A (0.92) | TDP1KMT2ASLC6A2SLC6A3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100145105-A1 | NOVEL PHENYLBORONIC ACID COMPOUNDS AND INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | US | disclosed |
| US-7700657-B2 | Vitamin D analogs | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-04-20 | — | — | US | disclosed |
| US-20100087669-A1 | NOVEL PHENYLBORONIC ACID COMPOUNDS AND INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-04-08 | — | — | US | disclosed |
| US-7659421-B2 | Phenylboronic acid compounds and intermediates and processes for the preparation thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-02-09 | — | — | US | disclosed |
| US-20070015931-A1 | Novel phenylboronic acid compounds and intermediates and processes for the preparation thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-01-18 | — | — | US | disclosed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | disclosed |
| US-6831106-B1 | Selective activity on cell proliferation and differentiation without displaying any hypercalcaemiant nature | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-12-14 | — | — | US | disclosed |
| US-20040224929-A1 | Novel vitamin D analogs | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-11-11 | — | — | US | disclosed |
| US-20030195259-A1 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015931-A1 | Novel phenylboronic acid compounds and intermediates and processes for the preparation thereof | VDR, CYP24A1, CYP2R1 | TDP1 4591/4885KMT2A 4589/4885SLC6A2 2217/4885 |
| US-20030195259-A1 | Triaromatic vitamin D analogues | CYP24A1, CYP2R1, VDR | TDP1 1791/4885KMT2A 4353/4885SLC6A2 4665/4885 |
| US-20100145105-A1 | NOVEL PHENYLBORONIC ACID COMPOUNDS AND INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF | VDR, CYP24A1, CYP2R1 | TDP1 4591/4885KMT2A 4589/4885SLC6A2 2217/4885 |
| US-20100087669-A1 | NOVEL PHENYLBORONIC ACID COMPOUNDS AND INTERMEDIATES AND PROCESSES FOR THE PREPARATION THEREOF | VDR, CYP24A1, CYP2R1 | TDP1 4591/4885KMT2A 4589/4885SLC6A2 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.